Author: Ravi Shankar

MAHIA, New Zealand, Oct. 23, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today launched its Electron rocket to deliver a dedicated mission to space for HawkEye 360, a signals intelligence data and analytics company.

The ‘We’re Not Hawking Around’ mission launched from Rocket Lab Launch Complex 1 in New Zealand at 8:11 p.m. NZDT on 23 October 2026, to deliver three HAWK satellites to a 520km low Earth orbit. Operating in tri-satellite formation, HawkEye 360’s satellites collect signal data from across the radio frequency (RF) spectrum for maritime tracking, GNSS jamming detection, radar monitoring, communications mapping, and space defense.

Today’s mission was Rocket Lab’s 98th Electron launch and 19^th launch this year, further extending the vehicle’s record as the most prolific launcher globally dedicated to small satellites.

Mission Highlights:

• Proven Constellation Partnership: Today’s launch success marks the third Electron launch dedicated to deploying HawkEye 360’s RF-sensing satellites, underscoring Rocket Lab’s trusted role in scaling commercial constellations for its customers.
• Rapid Launch Cadence: Now at 19 successful missions in 2026 alone, Rocket Lab continues to demonstrate the turnaround speed, high production rate, and schedule assurance demanded by modern commercial satellite companies and defense operators.
• Milestone Small Launch Leadership: This 98^th Electron flight moves Rocket Lab closer to a record 100 launches, solidifying the launch vehicle’s position as the world’s premier, most frequently launched dedicated small orbital rocket.

‘We’re Not Hawking Around’ launch images: click here

‘We’re Not Hawking Around’ launch broadcast: click here

Rocket Lab Media Contact
Murielle Baker
media@rocketlabusa.com

About Rocket Lab
Rocket Lab (Nasdaq: RKLB) is an end-to-end space company delivering rockets, satellites, and spacecraft components for commercial, government, and defense missions. Driven by its industry-leading small-lift rockets Electron and HASTE and its upcoming reusable Neutron medium-lift rocket, Rocket Lab delivers reliable and responsive launch for the world’s most important missions from constellation deployment to missile defense. Rocket Lab’s satellites and components have powered more than 1,700 missions in Earth orbit, as well as deep-space exploration of the Moon, Mars, and beyond. Learn more at www.rocketlabcorp.com.

Forward Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at  https://investors.rocketlabcorp.com which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Hydro’s adjusted EBITDA for the third quarter of 2026 was NOK 9,089 million, up from NOK 5,996 million in the same quarter last year. Higher all-in metal prices and higher alumina prices contributed positively in the quarter, along with improved earnings in Recycling and Extrusions. The strong performance was partially offset by higher anode and energy costs in Aluminium Metal, increased energy costs in Bauxite & Alumina due to gas supply disruptions, a stronger NOK vs USD, and negative price area differences in Energy.

• Alunorte resumed regular operations following temporary gas supply disruptions 

• Free cash flow of NOK 1.4 billion impacted by higher metal prices and associated working capital requirements and prepayments

• First metal produced at HalZero test facility, marking important milestone for carbon-free technology track

• Commercial momentum continues for Hydro’s low-carbon and recycled aluminium portfolio

• New PPAs secured, further strengthening Hydro’s long-term power position

Hydro delivered strong profitability in the quarter, with adjusted earnings per share increasing from NOK 1.0 in the third quarter of 2025, to NOK 2.3 in the third quarter of 2026. Free cash flow was NOK 1.4 billion, as strong adjusted EBITDA was partly offset by higher net operating capital, primarily driven by increased metal prices and associated working capital requirements and prepayments. While this development reflects the current market environment, improving cash conversion and working capital efficiency remains a clear priority going forward. Consequently, Hydro has updated its year-end capex guiding to around NOK 12.5 billion, down from NOK 13.5 billion, and net working capital guiding to around NOK 32 billion, up from NOK 30 billion. The twelve month adjusted RoaCE ended at 12.5 percent.

“Hydro’s third quarter results reflect strong operational performance amplified by market tailwinds. Record high liquid metal production from our Norwegian smelter system, combined with strong pricing throughout the quarter drove solid earnings and strong profitability. Operational excellence enables us to capture more of the upside when markets are strong and, more importantly, builds resilience when markets turn,” says Eivind Kallevik, President and CEO of Hydro. 

During the third quarter, disruption in natural gas supplies to Alunorte temporarily reduced production at the refinery. Through mitigating actions, including securing alternative LNG supply, Hydro maintained operational continuity and successfully restored alumina production.

Aluminium Metal benefited from higher all-in metal prices and strong operational performance, while Recycling and Extrusions delivered improved earnings supported by strong recycling margins. Hydro’s Norwegian smelters increased liquid metal production to record levels, reinforcing Hydro’s position as a reliable supplier of low-carbon aluminium to European customers.

In parallel, Hydro experienced continued momentum for its low-carbon and recycled products, with leading brands like CHANEL Fragrances and Beauty, General Motors, and Mercedes-Benz integrating Hydro’s solutions in their product lines.

“We continue to see strong demand for our low-carbon and recycled offerings from some of the world’s leading consumer brands. When brands like CHANEL Fragrances and Beauty and Mercedes-Benz choose Hydro, they place their trust in our quality, reliability, and ability to help them achieve their ambitions. That trust has commercial value and reinforces our confidence in the long-term opportunities for low-carbon and recycled aluminium,” says Kallevik.

Hydro reached an important milestone in the development of its HalZero technology by producing aluminium for the first time, demonstrating the core electrolysis technology beyond laboratory scale. The achievement marks an important step toward Hydro’s long-term ambition of eliminating emissions from electrolysis and anode production. Further testing, piloting and technology development remain before any potential industrial application. Enova awarded NOK 82 million in funding to support the concept development and planning of an industrial concept pilot.

“This is an important milestone and a significant step forward in the development of HalZero. Producing the first metal demonstrates that the electrolysis technology works and paves the way for the continued development of a game changing technology with the potential to enable emission-free aluminium production in the future,” says Kallevik.

During the quarter, Slovalco began the restart of primary aluminium production following the agreement announced in July on long-term framework conditions with the Slovak government. The restart commenced in late August, marking the return of capacity curtailed during the European energy crisis in 2022. The first phase targets an annual production capacity of 75,000 tonnes by the end of February 2027. The restart reflects the importance of competitive power, predictable regulatory frameworks, and effective industrial policy in maintaining and rebuilding Europe’s industrial base.

Results and market development per business area

Adjusted EBITDA for Bauxite & Alumina decreased compared to the third quarter of last year, to NOK 283 million from NOK 1,290 million, mainly driven by lower alumina sales prices, natural gas supply disruptions resulting in higher LNG sourcing costs and unfavourable BRL/USD exchange rate effects.This was partly offset by lower raw material costs and lower fixed costs.

PAX traded up throughout the third quarter 2026 to USD 370 per mt at the end on the quarter, diverging from Chinese alumina prices moving down. Despite lower alumina production at certain refineries in Indonesia because of raw material supply challenges, the World ex-China alumina market was oversupplied in the quarter. China’s alumina market became increasingly oversupplied during the quarter as new refinery capacity came on line.  Chinese alumina prices were close to the marginal cash production cost. Approximately half of China’s alumina production depends on bauxite imported from Guinea. The government of Guinea is considering the possibility of restricting annual bauxite exports volume, but no formal announcement has been made.

Adjusted EBITDA for Energy decreased in the third quarter compared to the same period last year, to NOK 411 million from NOK 828 million. The decrease is mainly due to a loss on price area differences compared to a gain in the same period last year.

Average Nordic power prices increased in the third quarter compared with both the previous quarter and the same quarter last year. The increase was mainly driven by weak hydrological conditions and higher power prices in Continental Europe. Price area differences between the south and north of the Nordic market were above the previous quarter and below the same period last year. The price difference between central Norway and northern Sweden widened significantly compared with both the previous quarter and the same quarter last year.

The Nordic hydrological balance at the end of the quarter was 13 TWh below normal, compared to 15 TWh below normal at the end of last quarter and 1 TWh below normal at the same time last year. Norwegian hydropower reservoirs were around 67.8 percent of full capacity at the end of the quarter, which is below the normal for this time of year of 82.8 percent. The distribution was uneven, with lower than normal levels in the southern and central Norway, and higher than normal levels in the north.

Adjusted EBITDA for Aluminium Metal increased in the third quarter of 2026 compared to the third quarter of 2025, to NOK 7,031 million from NOK 2,732 million, due to higher all-in metal prices, partly offset by lower sales volume, higher energy and carbon cost, and weaker USD to NOK. Global primary aluminium consumption was slightly higher compared to the third quarter of 2025, driven by a 3.0 percent increase in Asia. Primary consumption in the World ex. China is estimated to be down compared to the third quarter of 2025. The Middle East crisis continued to affect the aluminium market and prices during the third quarter. Following indications that the conflict might be nearing an end at the end of the second quarter, tensions increased again in the third quarter, directly contributing to higher aluminium prices. Throughout the quarter the market traded in a range between USD 3,100 per mt and USD 3,300 per mt. Consequently, the three month aluminium price increased slightly throughout the third quarter of 2026, starting the quarter at USD 3,076 per mt and ending at USD 3,170 per mt. 

Adjusted EBITDA for Metal Markets decreased in the third quarter of 2026 compared to the same period last year, to NOK 125 million from NOK 154 million, due to lower results from sourcing and trading activities, partly offset by higher results from recyclers.

Adjusted EBITDA for Extrusions increased in the third quarter of 2026 compared to the same quarter last year, to NOK 1,189 million from NOK 1,107 million, driven by higher recycling margins in combination with increased sales volume, partly offset by higher maintenance cost, higher SG&A cost and negative currency effects mainly from stronger NOK/USD.

CRU estimates that European extrusion demand increased by 1 percent in the third quarter of 2026 compared to the same quarter last year, following weaker market conditions in the first half of the year. Automotive demand remained positive, supported by continued growth in battery electric vehicle production. Non-automotive transportation also turned positive after a weak start to the year, while building and construction remained broadly stable in the quarter.

CRU estimates that North American extrusion demand remained broadly unchanged in the third quarter of 2026 compared to the same quarter last year, following a decline in the first half of the year. Commercial transportation continued to grow, supported by improving truckload rates, with further growth expected going forward. The industrial segment also remained solid, supported in part by continued datacenter investments. Automotive demand remained subdued, reflecting persistent headwinds in electric vehicle production.

Other key financials

Compared to the second quarter of 2026, Hydro’s adjusted EBITDA increased to NOK 9,089 million from NOK 8,923 million, mainly due to higher all-in metal and alumina prices and lower fixed costs in the third quarter of the year. This was partially offset by higher energy costs in Bauxite & Alumina due to gas supply disruptions and seasonally lower Extrusion volumes and margins.

Net income (loss) amounted to NOK 5,263 million in the third quarter of 2026. Net income (loss) included unrealized derivative losses, mainly on LME related contracts of NOK 204 million, environmental cost of NOK 111 million, rationalization charges and closure costs of NOK 81 million, and impairment charges on fixed assets of NOK 70 million. The tax effect on these adjustments reflected a standardized tax rate for taxable gains and tax deductible losses. Adjusted net income (loss) for the first quarter ended at NOK 4,372 million.

Hydro’s net debt decreased from NOK 16.3 billion to NOK 15.4 billion during the third quarter of 2026. The net debt decrease was mainly due to positive EBITDA contributions, partially offset by net operating capital build, investments and negative other operating cash flow.

Adjusted net debt decreased from NOK 22.8 billion to NOK 21.9 billion, mainly driven by the decrease in net debt.

Reported earnings before financial items and tax (EBIT), and net income include effects that are disclosed in the quarterly report. Adjustments to EBITDA, EBIT, and net income (loss) are defined and described as part of the alternative performance measures (APM) section in the quarterly report.

Investor contact: 

Gerd Aalborg Aas

+47 91305534

gerd.aalborg.aas@hydro.com

Valentina Gandolfi

+47 95882355

Valentina.Gandolfi@hydro.com 

Media contact: 

Halvor Molland 

+47 92979797

Halvor.Molland@hydro.com

The information was submitted for publication from Hydro Investor Relations and the contact persons set out above. Certain statements included in this announcement contain forward-looking information, including, without limitation, information relating to (a) forecasts, projections and estimates, (b) statements of Hydro management concerning plans, objectives and strategies, such as planned expansions, investments, divestments, curtailments or other projects, (c) targeted production volumes and costs, capacities or rates, start-up costs, cost reductions and profit objectives, (d) various expectations about future developments in Hydro’s markets, particularly prices, supply and demand and competition, (e) results of operations, (f) margins, (g) growth rates, (h) risk management, and (i) qualified statements such as “expected”, “scheduled”, “targeted”, “planned”, “proposed”, “intended” or similar. Although we believe that the expectations reflected in such forward-looking statements are reasonable, these forward-looking statements are based on a number of assumptions and forecasts that, by their nature, involve risk and uncertainty.  

Various factors could cause our actual results to differ materially from those projected in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to: our continued ability to reposition and restructure our upstream and downstream businesses; changes in availability and cost of energy and raw materials; global supply and demand for aluminium and aluminium products; world economic growth, including rates of inflation and industrial production; changes in the relative value of currencies and the value of commodity contracts; trends in Hydro’s key markets and competition; and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Except where required by law, Hydro disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

Attachments

• Third Quarter Report 2026
• NHY presentation Q3 2026

Hydro’s adjusted EBITDA for the third quarter of 2026 was NOK 9,089 million, up from NOK 5,996 million in the same quarter last year. Higher all-in metal prices and higher alumina prices contributed positively in the quarter, along with improved earnings in Recycling and Extrusions. The strong performance was partially offset by higher anode and energy costs in Aluminium Metal, increased energy costs in Bauxite & Alumina due to gas supply disruptions, a stronger NOK vs USD, and negative price area differences in Energy.

• Alunorte resumed regular operations following temporary gas supply disruptions 

• Free cash flow of NOK 1.4 billion impacted by higher metal prices and associated working capital requirements and prepayments

• First metal produced at HalZero test facility, marking important milestone for carbon-free technology track

• Commercial momentum continues for Hydro’s low-carbon and recycled aluminium portfolio

• New PPAs secured, further strengthening Hydro’s long-term power position

Hydro delivered strong profitability in the quarter, with adjusted earnings per share increasing from NOK 1.0 in the third quarter of 2025, to NOK 2.3 in the third quarter of 2026. Free cash flow was NOK 1.4 billion, as strong adjusted EBITDA was partly offset by higher net operating capital, primarily driven by increased metal prices and associated working capital requirements and prepayments. While this development reflects the current market environment, improving cash conversion and working capital efficiency remains a clear priority going forward. Consequently, Hydro has updated its year-end capex guiding to around NOK 12.5 billion, down from NOK 13.5 billion, and net working capital guiding to around NOK 32 billion, up from NOK 30 billion. The twelve month adjusted RoaCE ended at 12.5 percent.

“Hydro’s third quarter results reflect strong operational performance amplified by market tailwinds. Record high liquid metal production from our Norwegian smelter system, combined with strong pricing throughout the quarter drove solid earnings and strong profitability. Operational excellence enables us to capture more of the upside when markets are strong and, more importantly, builds resilience when markets turn,” says Eivind Kallevik, President and CEO of Hydro. 

During the third quarter, disruption in natural gas supplies to Alunorte temporarily reduced production at the refinery. Through mitigating actions, including securing alternative LNG supply, Hydro maintained operational continuity and successfully restored alumina production.

Aluminium Metal benefited from higher all-in metal prices and strong operational performance, while Recycling and Extrusions delivered improved earnings supported by strong recycling margins. Hydro’s Norwegian smelters increased liquid metal production to record levels, reinforcing Hydro’s position as a reliable supplier of low-carbon aluminium to European customers.

In parallel, Hydro experienced continued momentum for its low-carbon and recycled products, with leading brands like CHANEL Fragrances and Beauty, General Motors, and Mercedes-Benz integrating Hydro’s solutions in their product lines.

“We continue to see strong demand for our low-carbon and recycled offerings from some of the world’s leading consumer brands. When brands like CHANEL Fragrances and Beauty and Mercedes-Benz choose Hydro, they place their trust in our quality, reliability, and ability to help them achieve their ambitions. That trust has commercial value and reinforces our confidence in the long-term opportunities for low-carbon and recycled aluminium,” says Kallevik.

Hydro reached an important milestone in the development of its HalZero technology by producing aluminium for the first time, demonstrating the core electrolysis technology beyond laboratory scale. The achievement marks an important step toward Hydro’s long-term ambition of eliminating emissions from electrolysis and anode production. Further testing, piloting and technology development remain before any potential industrial application. Enova awarded NOK 82 million in funding to support the concept development and planning of an industrial concept pilot.

“This is an important milestone and a significant step forward in the development of HalZero. Producing the first metal demonstrates that the electrolysis technology works and paves the way for the continued development of a game changing technology with the potential to enable emission-free aluminium production in the future,” says Kallevik.

During the quarter, Slovalco began the restart of primary aluminium production following the agreement announced in July on long-term framework conditions with the Slovak government. The restart commenced in late August, marking the return of capacity curtailed during the European energy crisis in 2022. The first phase targets an annual production capacity of 75,000 tonnes by the end of February 2027. The restart reflects the importance of competitive power, predictable regulatory frameworks, and effective industrial policy in maintaining and rebuilding Europe’s industrial base.

Results and market development per business area

Adjusted EBITDA for Bauxite & Alumina decreased compared to the third quarter of last year, to NOK 283 million from NOK 1,290 million, mainly driven by lower alumina sales prices, natural gas supply disruptions resulting in higher LNG sourcing costs and unfavourable BRL/USD exchange rate effects.This was partly offset by lower raw material costs and lower fixed costs.

PAX traded up throughout the third quarter 2026 to USD 370 per mt at the end on the quarter, diverging from Chinese alumina prices moving down. Despite lower alumina production at certain refineries in Indonesia because of raw material supply challenges, the World ex-China alumina market was oversupplied in the quarter. China’s alumina market became increasingly oversupplied during the quarter as new refinery capacity came on line.  Chinese alumina prices were close to the marginal cash production cost. Approximately half of China’s alumina production depends on bauxite imported from Guinea. The government of Guinea is considering the possibility of restricting annual bauxite exports volume, but no formal announcement has been made.

Adjusted EBITDA for Energy decreased in the third quarter compared to the same period last year, to NOK 411 million from NOK 828 million. The decrease is mainly due to a loss on price area differences compared to a gain in the same period last year.

Average Nordic power prices increased in the third quarter compared with both the previous quarter and the same quarter last year. The increase was mainly driven by weak hydrological conditions and higher power prices in Continental Europe. Price area differences between the south and north of the Nordic market were above the previous quarter and below the same period last year. The price difference between central Norway and northern Sweden widened significantly compared with both the previous quarter and the same quarter last year.

The Nordic hydrological balance at the end of the quarter was 13 TWh below normal, compared to 15 TWh below normal at the end of last quarter and 1 TWh below normal at the same time last year. Norwegian hydropower reservoirs were around 67.8 percent of full capacity at the end of the quarter, which is below the normal for this time of year of 82.8 percent. The distribution was uneven, with lower than normal levels in the southern and central Norway, and higher than normal levels in the north.

Adjusted EBITDA for Aluminium Metal increased in the third quarter of 2026 compared to the third quarter of 2025, to NOK 7,031 million from NOK 2,732 million, due to higher all-in metal prices, partly offset by lower sales volume, higher energy and carbon cost, and weaker USD to NOK. Global primary aluminium consumption was slightly higher compared to the third quarter of 2025, driven by a 3.0 percent increase in Asia. Primary consumption in the World ex. China is estimated to be down compared to the third quarter of 2025. The Middle East crisis continued to affect the aluminium market and prices during the third quarter. Following indications that the conflict might be nearing an end at the end of the second quarter, tensions increased again in the third quarter, directly contributing to higher aluminium prices. Throughout the quarter the market traded in a range between USD 3,100 per mt and USD 3,300 per mt. Consequently, the three month aluminium price increased slightly throughout the third quarter of 2026, starting the quarter at USD 3,076 per mt and ending at USD 3,170 per mt. 

Adjusted EBITDA for Metal Markets decreased in the third quarter of 2026 compared to the same period last year, to NOK 125 million from NOK 154 million, due to lower results from sourcing and trading activities, partly offset by higher results from recyclers.

Adjusted EBITDA for Extrusions increased in the third quarter of 2026 compared to the same quarter last year, to NOK 1,189 million from NOK 1,107 million, driven by higher recycling margins in combination with increased sales volume, partly offset by higher maintenance cost, higher SG&A cost and negative currency effects mainly from stronger NOK/USD.

CRU estimates that European extrusion demand increased by 1 percent in the third quarter of 2026 compared to the same quarter last year, following weaker market conditions in the first half of the year. Automotive demand remained positive, supported by continued growth in battery electric vehicle production. Non-automotive transportation also turned positive after a weak start to the year, while building and construction remained broadly stable in the quarter.

CRU estimates that North American extrusion demand remained broadly unchanged in the third quarter of 2026 compared to the same quarter last year, following a decline in the first half of the year. Commercial transportation continued to grow, supported by improving truckload rates, with further growth expected going forward. The industrial segment also remained solid, supported in part by continued datacenter investments. Automotive demand remained subdued, reflecting persistent headwinds in electric vehicle production.

Other key financials

Compared to the second quarter of 2026, Hydro’s adjusted EBITDA increased to NOK 9,089 million from NOK 8,923 million, mainly due to higher all-in metal and alumina prices and lower fixed costs in the third quarter of the year. This was partially offset by higher energy costs in Bauxite & Alumina due to gas supply disruptions and seasonally lower Extrusion volumes and margins.

Net income (loss) amounted to NOK 5,263 million in the third quarter of 2026. Net income (loss) included unrealized derivative losses, mainly on LME related contracts of NOK 204 million, environmental cost of NOK 111 million, rationalization charges and closure costs of NOK 81 million, and impairment charges on fixed assets of NOK 70 million. The tax effect on these adjustments reflected a standardized tax rate for taxable gains and tax deductible losses. Adjusted net income (loss) for the first quarter ended at NOK 4,372 million.

Hydro’s net debt decreased from NOK 16.3 billion to NOK 15.4 billion during the third quarter of 2026. The net debt decrease was mainly due to positive EBITDA contributions, partially offset by net operating capital build, investments and negative other operating cash flow.

Adjusted net debt decreased from NOK 22.8 billion to NOK 21.9 billion, mainly driven by the decrease in net debt.

Reported earnings before financial items and tax (EBIT), and net income include effects that are disclosed in the quarterly report. Adjustments to EBITDA, EBIT, and net income (loss) are defined and described as part of the alternative performance measures (APM) section in the quarterly report.

Investor contact: 

Gerd Aalborg Aas

+47 91305534

gerd.aalborg.aas@hydro.com

Valentina Gandolfi

+47 95882355

Valentina.Gandolfi@hydro.com 

Media contact: 

Halvor Molland 

+47 92979797

Halvor.Molland@hydro.com

The information was submitted for publication from Hydro Investor Relations and the contact persons set out above. Certain statements included in this announcement contain forward-looking information, including, without limitation, information relating to (a) forecasts, projections and estimates, (b) statements of Hydro management concerning plans, objectives and strategies, such as planned expansions, investments, divestments, curtailments or other projects, (c) targeted production volumes and costs, capacities or rates, start-up costs, cost reductions and profit objectives, (d) various expectations about future developments in Hydro’s markets, particularly prices, supply and demand and competition, (e) results of operations, (f) margins, (g) growth rates, (h) risk management, and (i) qualified statements such as “expected”, “scheduled”, “targeted”, “planned”, “proposed”, “intended” or similar. Although we believe that the expectations reflected in such forward-looking statements are reasonable, these forward-looking statements are based on a number of assumptions and forecasts that, by their nature, involve risk and uncertainty.  

Various factors could cause our actual results to differ materially from those projected in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to: our continued ability to reposition and restructure our upstream and downstream businesses; changes in availability and cost of energy and raw materials; global supply and demand for aluminium and aluminium products; world economic growth, including rates of inflation and industrial production; changes in the relative value of currencies and the value of commodity contracts; trends in Hydro’s key markets and competition; and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Except where required by law, Hydro disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

Attachments

• Third Quarter Report 2026
• NHY presentation Q3 2026

CERTIFICATE MATURITY	261028
FIXED RATE (STEERING RATE + 10 b.p.)	1.85 %
VOLUME BOUGHT	10.00 BLN
TRADE DAY	261023
SETTLEMENT DAY	261026

CERTIFICATE MATURITY	261028
FIXED RATE (STEERING RATE + 10 b.p.)	1.85 %
VOLUME BOUGHT	10.00 BLN
TRADE DAY	261023
SETTLEMENT DAY	261026

Auction date	2026-10-23
Loan	3114
Coupon	0.125 %
ISIN-code	SE0013748258
Maturity	2030-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	1,100
Volume sold, SEK mln	200
Number of bids	11
Number of accepted bids	1
Average yield	0.789 %
Lowest yield	0.789 %
Highest accepted yield	0.789 %
% accepted at highest yield	100.00

 

Auction date	2026-10-23
Loan	3111
Coupon	0.125 %
ISIN-code	SE0007045745
Maturity	2032-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	650
Volume sold, SEK mln	200
Number of bids	7
Number of accepted bids	4
Average yield	0.940 %
Lowest yield	0.930 %
Highest accepted yield	0.949 %
% accepted at highest yield	25.00

 

Auction date	2026-10-23
Loan	3114
Coupon	0.125 %
ISIN-code	SE0013748258
Maturity	2030-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	1,100
Volume sold, SEK mln	200
Number of bids	11
Number of accepted bids	1
Average yield	0.789 %
Lowest yield	0.789 %
Highest accepted yield	0.789 %
% accepted at highest yield	100.00

 

Auction date	2026-10-23
Loan	3111
Coupon	0.125 %
ISIN-code	SE0007045745
Maturity	2032-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	650
Volume sold, SEK mln	200
Number of bids	7
Number of accepted bids	4
Average yield	0.940 %
Lowest yield	0.930 %
Highest accepted yield	0.949 %
% accepted at highest yield	25.00

 

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk nonmetastatic prostate cancer. The findings will be presented tomorrow in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 by Dr. Sarah Howlett of University College London (UCL).

The retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher in men with clinically very high-risk nonmetastatic prostate cancer. This predictive evidence bolsters Decipher’s high-risk claims to help physicians identify which patients are most likely to benefit from adding abiraterone to ADT. These findings build on Decipher’s long-established standing in guidelines for assessing the risk of cancer progression, as well as prior STAMPEDE analysis that was recently incorporated into the NCCN 2027 prostate cancer guidelines for high- and very high-risk disease.

For patients with very high-risk disease, the decision to add abiraterone treatment carries significant consequences. Abiraterone can improve cancer outcomes when added to ADT but also adds side effects and treatment burden. Understanding a patient’s expected benefit from the additional treatment can help physicians and patients weigh the potential benefit alongside the impact on daily life.

“For men with very high-risk disease, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference,” said Dr. Sarah Howlett, clinical research fellow in the Research Department of Oncology at UCL and the study’s presenter. “This analysis shows that the Decipher test can identify which patients in this study population were at greatest risk of prostate cancer-specific mortality and, therefore, may gain the greatest benefit from adding abiraterone to ADT. That gives physicians and patients evidence to make more confident treatment decisions based on the biology of the individual tumor.”

Key study findings in very high-risk patients:

• Decipher predicted benefit from adding abiraterone. The treatment-by-Decipher interaction for distant metastasis was statistically significant among node-negative patients (p=0.01), indicating that treatment benefit differed according to the Decipher score.
• Patients with higher Decipher scores saw greater benefit. At five years, the absolute benefit for adding abiraterone in terms of reducing distant metastasis events was 10% for patients with high scores and 11% for those with very high scores, compared to 2% benefit for those with lower scores.
• Decipher scores identified differences in the risk of cancer spread. Higher scores were associated with greater distant-metastasis risk and worse metastasis-free and overall survival in the STAMPEDE cohort. A separate analysis including data from over 27,000 real-world patients reinforced Decipher’s prognostic value across NCCN high- and very high-risk clinical groups.

The STAMPEDE analysis included 401 patients who received ADT alone or ADT plus abiraterone. The separate real-world analysis evaluated associations between Decipher scores and patient outcomes; it was not designed to assess prediction of abiraterone benefit.

“These findings expand Decipher’s predictive evidence to another consequential treatment decision: whether adding abiraterone will provide meaningful benefit for a man with very high-risk prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “Building on the predictive data recently presented in intermediate-risk disease at ASTRO, these results strengthen Decipher’s role in helping physicians connect tumor biology to treatment selection across the prostate cancer risk continuum. We believe this growing evidence gives physicians a stronger reason to use Decipher before making decisions that can affect both cancer outcomes and patients’ quality of life.”

Decipher is already used in the care of patients with high-risk prostate cancer. The new findings strengthen the clinical rationale for testing before treatment-intensification decisions and support the potential for broader adoption and use in this population. Another trial prospectively evaluating the use of the Decipher test to guide treatment intensification or de-intensification in high-risk prostate cancer is the phase III biomarker-driven NRG-GU009 (PREDICT-RT) study, which completed enrollment earlier this year. This trial will add prospective evidence to the findings from the STAMPEDE trial, further expanding the predictive evidence around the Decipher test for treatment intensification with apalutamide, a different androgen receptor pathway inhibitor.

ESMO 2026 presentation

• Title: Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically high-risk prostate cancer
• Presenter: Dr. Sarah Howlett, University College London
• Date and time: October 24, 2026 at 10:15–11:45 a.m. CEST

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential clinical utility, impact and benefits of the Decipher Prostate Genomic Classifier; the ability of the Decipher Prostate test to predict which patients with very high-risk, nonmetastatic prostate cancer may benefit from the addition of abiraterone to ADT; the potential use of Decipher to inform treatment selection, including treatment-intensification decisions, and personalize treatment decisions; the potential for Decipher to help physicians connect tumor biology to treatment selection across the prostate cancer risk continuum; the potential for broader adoption and use in patients with very high-risk, nonmetastatic prostate cancer; the significance and clinical implications of the study findings; and the potential outcomes, validation and impact of the ongoing Phase III PREDICT-RT clinical trial. Forward-looking statements can be identified by words such as “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk nonmetastatic prostate cancer. The findings will be presented tomorrow in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 by Dr. Sarah Howlett of University College London (UCL).

The retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher in men with clinically very high-risk nonmetastatic prostate cancer. This predictive evidence bolsters Decipher’s high-risk claims to help physicians identify which patients are most likely to benefit from adding abiraterone to ADT. These findings build on Decipher’s long-established standing in guidelines for assessing the risk of cancer progression, as well as prior STAMPEDE analysis that was recently incorporated into the NCCN 2027 prostate cancer guidelines for high- and very high-risk disease.

For patients with very high-risk disease, the decision to add abiraterone treatment carries significant consequences. Abiraterone can improve cancer outcomes when added to ADT but also adds side effects and treatment burden. Understanding a patient’s expected benefit from the additional treatment can help physicians and patients weigh the potential benefit alongside the impact on daily life.

“For men with very high-risk disease, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference,” said Dr. Sarah Howlett, clinical research fellow in the Research Department of Oncology at UCL and the study’s presenter. “This analysis shows that the Decipher test can identify which patients in this study population were at greatest risk of prostate cancer-specific mortality and, therefore, may gain the greatest benefit from adding abiraterone to ADT. That gives physicians and patients evidence to make more confident treatment decisions based on the biology of the individual tumor.”

Key study findings in very high-risk patients:

• Decipher predicted benefit from adding abiraterone. The treatment-by-Decipher interaction for distant metastasis was statistically significant among node-negative patients (p=0.01), indicating that treatment benefit differed according to the Decipher score.
• Patients with higher Decipher scores saw greater benefit. At five years, the absolute benefit for adding abiraterone in terms of reducing distant metastasis events was 10% for patients with high scores and 11% for those with very high scores, compared to 2% benefit for those with lower scores.
• Decipher scores identified differences in the risk of cancer spread. Higher scores were associated with greater distant-metastasis risk and worse metastasis-free and overall survival in the STAMPEDE cohort. A separate analysis including data from over 27,000 real-world patients reinforced Decipher’s prognostic value across NCCN high- and very high-risk clinical groups.

The STAMPEDE analysis included 401 patients who received ADT alone or ADT plus abiraterone. The separate real-world analysis evaluated associations between Decipher scores and patient outcomes; it was not designed to assess prediction of abiraterone benefit.

“These findings expand Decipher’s predictive evidence to another consequential treatment decision: whether adding abiraterone will provide meaningful benefit for a man with very high-risk prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “Building on the predictive data recently presented in intermediate-risk disease at ASTRO, these results strengthen Decipher’s role in helping physicians connect tumor biology to treatment selection across the prostate cancer risk continuum. We believe this growing evidence gives physicians a stronger reason to use Decipher before making decisions that can affect both cancer outcomes and patients’ quality of life.”

Decipher is already used in the care of patients with high-risk prostate cancer. The new findings strengthen the clinical rationale for testing before treatment-intensification decisions and support the potential for broader adoption and use in this population. Another trial prospectively evaluating the use of the Decipher test to guide treatment intensification or de-intensification in high-risk prostate cancer is the phase III biomarker-driven NRG-GU009 (PREDICT-RT) study, which completed enrollment earlier this year. This trial will add prospective evidence to the findings from the STAMPEDE trial, further expanding the predictive evidence around the Decipher test for treatment intensification with apalutamide, a different androgen receptor pathway inhibitor.

ESMO 2026 presentation

• Title: Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically high-risk prostate cancer
• Presenter: Dr. Sarah Howlett, University College London
• Date and time: October 24, 2026 at 10:15–11:45 a.m. CEST

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential clinical utility, impact and benefits of the Decipher Prostate Genomic Classifier; the ability of the Decipher Prostate test to predict which patients with very high-risk, nonmetastatic prostate cancer may benefit from the addition of abiraterone to ADT; the potential use of Decipher to inform treatment selection, including treatment-intensification decisions, and personalize treatment decisions; the potential for Decipher to help physicians connect tumor biology to treatment selection across the prostate cancer risk continuum; the potential for broader adoption and use in patients with very high-risk, nonmetastatic prostate cancer; the significance and clinical implications of the study findings; and the potential outcomes, validation and impact of the ongoing Phase III PREDICT-RT clinical trial. Forward-looking statements can be identified by words such as “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780

FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging FDA’s alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom’s new drug application (NDA) for VOQUEZNA®. In the suit, BDR alleges that FDA has improperly applied the GAIN Act to extend Phathom’s New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan fumarate) tablets. Phathom is evaluating the BDR filings, but believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom’s December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032. Phathom intends to take appropriate action to protect its statutory exclusivities.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements, including without limitation statements regarding: Phathom’s belief that FDA correctly evaluated and recognized the GAIN Act extension of the NCE exclusivity for VOQUEZNA tablets; Phathom’s intent to take appropriate actions to protect its statutory exclusivities; the expected duration of NCE exclusivity for VOQUEZNA tablets; and the potential timing and outcome of the litigation filed by BDR. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: BDR may succeed in its challenge to FDA’s recognition of the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets which would result in a reduction in the period of regulatory exclusivity and permit FDA to receive and potentially approve ANDAs referencing VOQUEZNA tablets earlier than currently anticipated; the litigation, including any appeals, may be lengthy, costly and distracting to management, and its timing and outcome are uncertain; developments in the litigation, or public perception of them, may hurt Phathom’s stock price, VOQUEZNA sales, or Phathom’s business, financial condition and prospects; Phathom may not be able to obtain and maintain intellectual property protection, including patent term extensions, and may not be able to maintain non-patent regulatory exclusivity for VOQUEZNA for the time periods it expects or at all; Phathom may be unsuccessful in defending its Orange Book-listed patents against challenges by third parties; Phathom may face competition earlier than expected if it loses any of regulatory or patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets, including as a result of an adverse outcome in the BDR litigation; and other risks described in Phathom’s prior press releases and filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to revise or update such statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.